Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezacaftor/Ivacaftor in CF with F508del and Gating Mutation
NCT02412111Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of tezacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Jun 2015; status: completed.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02412111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02412111.